A Descriptive Study on Quality of Life among Adolescents with Beta-Thalassemia Major in the Maldives

Shanooha Mansoor¹, Zahiruddin Othman², Azizah Othman², Maruzairi Husain²

ABSTRACT

Background: The Maldives has the highest prevalence of thalassemia in the world. However, there is little research done on the psychosocial aspects of this illness.

Objectives: This study aimed to examine health related quality of life (HRQOL) among adolescents with beta-thalassemia major attending the National Thalassemia and Other Hemoglobinopathies Centre (NTC), Maldives Blood Services, Maldives. Thus, appropriate recommendation could be proposed.

Methods: A total of 81 adolescents (mean age 15.7 years) with beta-thalassemia major were engaged. HRQOL was assessed using the Pediatric Quality of Life Inventory (PedsQL). Other relevant information was gathered through interview or medical record.

Results: The HRQOL was reduced. The mean for physical, emotional, social, school and psychosocial HRQOL was 80.50, 72.30, 88.18, 76.44, and 78.96, respectively. The total HRQOL was 79.50 and this was lower in females (75.29) compared to males (83.29). Ferritin levels of 1,001-2,499 μ g/l and > 2,500 μ g/l were noted in 34.2% and 53.9%, respectively. Good compliance was reported in 55% of participants.

Conclusions: Adolescents with beta-thalassemia major in the Maldives have reduced HRQOL. The high ferritin level could reduce the HRQOL and hence an attempt should be made towards lowering ferritin and improving compliance to chelation treatments. The gender difference in HRQOL signifies the need for more attention to the female patients and for areas of improvement to be explored.

KEY WORDS

thalassemia, quality of life, ferritin, iron overload, psychosocial

INTRODUCTION

The Republic of Maldives is an island nation of 350,000 people located in the Indian Ocean. It consists of 1900 islands, of which 200 are inhabited. It has one of the highest incidences of thalassemia and has the world's highest concentration of carriers at 16-18% of the population¹) thought to be due to prevalent consanguineous marriages in the past²). A total of 670 cases have been registered in the National Thalassemia and Other Hemoglobinopathies Centre. It is estimated that more than 30% of the population has been screened to date and the high percentage of carriers lead to 1 in every 120 child being born is a thalassemia major child³). Poor uptake of screening for the condition is one of the main reasons for this high number of new cases⁴).

The Maldivian government identified thalassemia as a national problem in the early 1990s, and took initiative involving awareness, education, the prevention and treatment programs.⁴⁾ Though thalassemia has been identified as an issue of national concern, the infrastructure still lacks the psychological support this group of adolescents need. The lack of awareness of this important aspect is highlighted by a number of patients as well as family members who were noted to have psychological and coping issues, among those met at the daycare centre and the NTC institute. Of note was the unintentional omission of this aspect of the disease in any of the support booklets or meetings carried out.

Beta-thalassemia major patients require regular blood transfusions which lead to iron overload and its complications. In addition, chronic hypoxia due to anemia further increases the toxicity of iron deposition on various organs.⁵⁾ Studies have found that high levels of ferritin are associated with diabetes mellitus, thyroid and parathyroid disorders as well as hypogonadism, with diabetes being the most common⁶⁻⁹⁾. Certain complications, especially those related to growth and other metabolic changes like delayed menses, has a negative impact on the thalassemia children. It has been highlighted that children often endured teasing due to their short-stature, and facies as well as "dark" skin colour leading to lower self-esteem, feeling stressed up and anxious¹⁰⁾.

Most studies have highlighted that adherence to subcutaneous iron chelation therapy was poor and the reasons were side effects, finding it difficult and burdensome as well as not wanting to do it¹⁰. Other studies have found older age, age at the start of treatment and emotional distress to be associated with low levels of adherence¹¹. Chronic illness and its treatment are associated with lower health related quality of life (HRQOL)¹². Similarly, studies had demonstrated HRQOL is significantly affected in children with beta-thalassemia major on regular transfusion across all age groups, gender and socio-economic classes and also in their caregivers¹³⁻¹⁶). Thus, improving on patients and maternal education is crucial as these factors are recognized as independent predictor of better HRQOL¹⁷).

At present the Maldives has a good program in place for the medi-

- © 2018 Japan Health Sciences University
 - & Japan International Cultural Exchange Foundation

Received on July 27, 2017 and accepted on August 2, 2017

¹⁾ Psychiatry Department, Indira Gandhi Memorial Hospital, Male Maldives

²⁾ School of Medical Sciences, Universiti Sains Malaysia 16150 Kubang Kerian, Kelantan, Malaysia

Correspondence to: Zahiruddin Othman

⁽e-mail: zahirkb@usm.my)

Table 1. Socio-demographic characteristics of subjects (N = 81)

Variables n (%) Gender 35 (43.2) Male 35 (43.2) Female 46 (56.8) Age (years) 10-11 5 (6.2) 12-13 14 (17.3) 14-16 29 (35.8) 17-19 33 (40.7) Schooling/occupational status Schooling 58 (73.4) Working 14 (17.7) Unemployed 7 (8.9) Number of siblings Working None 9 (11.1) 1-2 44 (54.3) 3-5 23 (28.4) > 5 5 (6.2) Siblings with thalassemia Working No 59 (72.8) Yes 22 (27.2) Academic performance Good Good 19 (27.5) Average 39 (56.5) Low 11 (16.0) Age of diagnosis 0 0-12 month 51 (75.0) 1-2 years 57.4) Oral 21 (26.6) Once a week 12 (15.2)	Table 1. Socio-demographic characteristi	
Male 35 (43.2) Female 46 (56.8) Age (years) 46 (56.8) 10-11 5 (6.2) 12-13 14 (17.3) 14-16 29 (35.8) 17-19 33 (40.7) Schooling/occupational status 58 (73.4) Working 14 (17.7) Unemployed 7 (8.9) Number of siblings 9 (11.1) 1-2 44 (54.3) 3-5 23 (28.4) > 5 5 (50.2) Siblings with thalassemia 9 (11.5) No 59 (72.8) Yes 22 (27.2) Academic performance 9 (36.5) Good 19 (27.5) Average 39 (56.5) Low 11 (16.0) Age of diagnosis 0 0-12 month 51 (75.0) 1-2 years 2 (17.6) > 2 years 5(7.1) Orca 6 (8.7) Oral 21 (30.4) Injectable 16 (23.1) Both	Variables	n (%)
Female46 (56.8)Age (years)10-115 (6.2)12-1314 (17.3)14-1629 (35.8)17-1933 (40.7)Schooling/occupational status $SchoolingSchooling58 (73.4)Working14 (17.7)Unemployed7 (8.9)Number of siblingsWNone9 (11.1)1-244 (54.3)3-523 (28.4)> 55 (5.2)Siblings with thalassemiaWNo59 (72.8)Yes22 (27.2)Academic performanceGGood19 (27.5)Average39 (56.5)Low11 (16.0)Age of diagnosisU0-12 month51 (75.0)1-2 years12 (17.6)> 2 years5(7.4)ChelationMNone6 (8.7)Oral21 (30.4)Injectable16 (23.1)Both26 (37.7)Blood transfusionUOnce a week21 (15.2)Once every 2 weeks44 (55.7)Once in > 4 weeks2 (2.5)Hemoglobin level (gm%)G6-713 (16.0)8-960 (74.1)> 98 (9.9)Ferritin levelNNormal (< 1,000 µ/1)$	Gender	
Age (years) 5 (6 2) 12-13 14 (17.3) 14-16 29 (35.8) 17-19 33 (407) Schooling/occupational status Schooling Schooling 5 (73.4) Working 14 (17.7) Unemployed 7 (8.9) Number of siblings 9 (11.1) 1-2 44 (54.3) 3-5 23 (28.4) > 5 5 (6.2) Siblings with thalassemia Working No 59 (72.8) Yes 22 (27.2) Academic performance Good Good 19 (27.5) Average 39 (56.5) Low 11 (16.0) Age of diagnosis 0 0-12 month 51 (75.0) 1-2 years (2 (17.6) > 2 years (2 (17.6) Oral 12 (17.6) > 2 years (2 (17.6) Orae week 12 (17.6) > 0 (11.0) (3 (17.	Male	35 (43.2)
10-11 5 (6.2) 12-13 14 (17.3) 14-16 29 (35.8) 17-19 32 Schooling/occupational status Schooling/occupational status Schooling 14 (17.7) Unemployed 7 (8.9) Number of siblings 9 (11.1) 1-2 44 (54.3) 3-5 23 (28.4) > 5 5 (6.2) Siblings with thalassemia Working No 59 (72.8) Yes 20 (27.5) Average 39 (56.5) Low 11 (16.0) Age of diagnosis 0 0-12 month 51 (75.0) 1-2 years 5 (7.4) Chelation 12 (130.4) None 6 (8.7) Oral 21 (30.4) Injectable 16 (23.1) Both 26 (37.7) Once aveek 12 (15.2) Once aveek 12 (15.2) Once aveek 12 (15.2) Once aveek 12 (15.2)	Female	46 (56.8)
12-13 14 (17.) 14-16 29 (35.8) 17-19 33 (40.7) Schooling/occupational status 5 Schooling 58 (73.4) Working 14 (17.7) Unemployed 7 (8.9) Number of siblings 9 (11.1) 1-2 44 (54.3) 3-5 23 (28.4) > 5 5 (6.2) Siblings with thalassemia 9 (9 (72.8) No 59 (72.8) Yes 22 (27.2) Academic performance 0 Good 19 (27.5) Average 39 (56.5) Low 11 (10.0) Age of diagnosis 0 0-12 month 51 (75.0) 1-2 years 5 (7.4) Chelation 10 None 6 (8.7) Oral 21 (30.4) Injectable 16 (23.1) Both 26 (37.7) Blood transfusion 21 (26.6) Once a week 12 (15.2) Once every 4 weeks 21 (26.6) Once overy 4 weeks 21 (26	Age (years)	
14-16 29 (35) 17-19 33 (40.7) Schooling/occupational status 58 (73.4) Working 14 (17.7) Unemployed 7 (8.9) Number of siblings 9 (11.1) 1-2 44 (54.3) 3-5 23 (28.4) > 5 5 (6.2) Siblings with thalassemia Working No 59 (72.8) Yes 22 (27.2) Academic performance Good Good 19 (27.5) Average 39 (56.5) Low 11 (16.0) Age of diagnosis 0 0-12 month 51 (75.0) 1-2 years 57 (7.4) Chelation 11 (16.0) None 6 (8.7) Oral 12 (17.6) > 2 years 57 (7.4) Chelation 26 (37.7) Blood transfusion 10 Once aveek 12 (15.2) Once aveek 12 (25.6) Once aveek 2 (2.5) H	10-11	5 (6.2)
17-19 33 (40.7) Schooling/occupational status 58 (73.4) Working 14 (17.7) Unemployed 7 (8.9) Number of siblings 9 (11.1) 1-2 44 (54.3) 3-5 23 (28.4) > 5 5 (6.2) Siblings with thalassemia V No 59 (72.8) Yes 22 (27.2) Academic performance 0 Good 19 (27.5) Average 39 (56.5) Low 11 (16.0) Age of diagnosis 0 $0-12$ month 51 (75.0) $1-2$ years 12 (17.6) > 2 years 5 (7.4) Chelation 0 None 6 (8.7) Oral 21 (30.4) Injectable 16 (23.1) Both 26 (37.7) Blood transfusion 0 Once aveek 21 (26.6) Once aveek 22 (2.5) Hemoglobin level (gm%) 6 $6-7$ 13 (16.0) $8-9$ 60 (74.1) <td>12-13</td> <td>14 (17.3)</td>	12-13	14 (17.3)
Schooling/occupational status Sk (73.4) Working 14 (17.7) Unemployed 7 (8.9) Number of siblings 9 (11.1) 1-2 44 (54.3) 3-5 23 (28.4) > 5 3 (6.2) Siblings with thalassemia $(1, 2, 3, 3)$ No 59 (72.8) Yes 22 (27.2) Academic performance $(1, 2, 3)$ Good 19 (27.5) Average 39 (56.5) Low 11 (16.0) Age of diagnosis $(-12 \mod m)$ 0-12 month 51 (75.0) 1-2 years 5 (7.4) Chelation (11.0) None 6 (8.7) Oral 21 (30.4) Injectable 16 (23.1) Both 26 (57.7) Once a week 12 (15.2) Once every 2 weeks 44 (55.7) Once every 2 weeks 44 (55.7) Once every 2 weeks 42 (2.5) Hemoglobin level (gm%) 6.7 6-7	14-16	29 (35.8)
Schooling 58 (73.4) Working 14 (17.7) Unemployed 7 (8.9) Number of siblings 9 (11.1) 1-2 44 (54.3) 3-5 23 (28.4) > 5 5 (5.2) Siblings with thalassemia (11.1) No 9 (11.1) 1-2 44 (54.3) 3-5 23 (28.4) > 5 Siblings with thalassemia No 59 (72.8) Yes 22 (27.2) Academic performance $(19.(27.5))$ Average 39 (56.5) Low 11 (16.0) Age of diagnosis (-12 month) 0-12 month 51 (75.0) 1-2 years 5 (7.4) Chelation $(21 (30.4))$ Injectable 16 (23.1) Both 26 (37.7) Blood transfusion $(2 (5.7))$ Once aveek $(2 (5.2))$ Hemoglobin level (gm%) (6.7) 6-7 13 (16.0) 8-9 $(0 (74.1))$ > 9 $(2 (34.2))$ Ver	17-19	33 (40.7)
Working 14 (17.7) Unemployed 7 (8.9) Number of siblings 9 (11.1) 1-2 44 (54.3) 3-5 23 (28.4) > 5 5 Siblings with thalassemia 0 No 59 (72.8) Yes 22 (27.2) Academic performance 39 (56.5) Low 11 (16.0) Age of diagnosis 0 0-12 month 51 (75.0) 1-2 years 32 (27.2) 2 years 51 (75.0) 1-2 years 32 (56.5) Low 11 (16.0) Age of diagnosis 0 0-12 month 51 (75.0) 1-2 years 52 (7.4) Chelation 6 (8.7) Oral 12 (17.6) > 2 years 52 (3.1) Both 26 (3.7.7) Blood transfusion 16 (23.1) Once a week 12 (15.2) Once a week 12 (15.2) Once or > 4 weeks 2 (2.5) He	Schooling/occupational status	
Unemployed 7 (8.9) Number of siblings 9 (11.1) 1-2 44 (54.3) 3-5 23 (28.4) > 5 5 (6.2) Siblings with thalassemia V No 59 (72.8) Yes 22 (27.2) Academic performance 0 Good 19 (27.5) Average 39 (56.5) Low 11 (16.0) Age of diagnosis 0 $0-12$ month 51 (75.0) 1-2 years 12 (17.6) > 2 years 5 (7.4) Chelation 6 (8.7) None 6 (8.7) Oral 21 (30.4) Injectable 16 (23.1) Both 26 (37.7) Blood transfusion 0 Once a week 12 (15.2) Once every 2 weeks 24 (25.5) Hemoglobin level (gm%) 6 6.7 13 (16.0) 8.9 8 (9.9) Ferritin level $Normal (\leq 1,000 \mu g/l)$ <	Schooling	58 (73.4)
Number of siblings 9 (11.1) 1-2 44 (54.3) 3-5 23 (28.4) > 5 5 (6.2) Siblings with thalassemia No No 59 (72.8) Yes 22 (27.2) Academic performance 0 Good 19 (27.5) Average 39 (56.5) Low 11 (16.0) Age of diagnosis 12 (17.6) 0-12 month 51 (75.0) 1-2 years 5 (7.4) Chelation 6 (8.7) None 6 (8.7) Oral 21 (30.4) Injectable 16 (23.1) Both 26 (37.7) Blood transfusion 21 (15.2) Once a week 12 (15.2) Once every 2 weeks 44 (55.7) Once overy 4 weeks 21 (26.6) Once in > 4 weeks 21 (26.6) Once in > 4 weeks 20 (2.5) Hemoglobin level (gm%) 6.7 6-7 13 (16.0) 8-9 8 (9.9) Ferritin level 9 Normal (≤ 1,000 µ	Working	14 (17.7)
None 9 (11.1) 1-2 44 (54.3) 3-5 23 (28.4) > 5 5 (6.2) Siblings with thalassemia No No 59 (72.8) Yes 22 (27.2) Academic performance Good Good 19 (27.5) Average 39 (56.5) Low 11 (16.0) Age of diagnosis 0 0-12 month 51 (75.0) 1-2 years 12 (17.6) > 2 years 5 (7.4) Chelation 0 None 6 (8.7) Oral 21 (30.4) Injectable 16 (23.1) Both 26 (37.7) Blood transfusion 21 (25.2) Once aveek 12 (15.2) Once every 2 weeks 24 (55.7) Once every 4 weeks 2 (2.5) Hemoglobin level (gm%) 6 6-7 13 (16.0) 8-9 60 (74.1) > 9 8 (9.9) Ferritin level <td< td=""><td>Unemployed</td><td>7 (8.9)</td></td<>	Unemployed	7 (8.9)
1-2 .44 (54.3) 3-5 .23 (28.4) > 5 .5 (6.2) Siblings with thalassemia	Number of siblings	
3-5 23 (28.4) ≥ 5 5 (6.2) Siblings with thalassemia 5 No 59 (72.8) Yes 22 (27.2) Academic performance 9 Good 19 (27.5) Average 39 (56.5) Low 11 (16.0) Age of diagnosis 0 0-12 month 51 (75.0) 1-2 years 12 (17.6) > 2 years 5 (7.4) Chelation 0 None 6 (8.7) Oral 21 (30.4) Injectable 16 (23.1) Both 26 (37.7) Blood transfusion 0 Once a week 12 (15.2) Once every 2 weeks 44 (55.7) Once every 4 weeks 21 (26.6) Once in > 4 weeks 2 (2.5) Hemoglobin level (gm%) 6-7 6-7 13 (16.0) 8-9 60 (74.1) > 9 8 (9.9) Ferritin level 9 Normal (≤ 1,000 µg/l) 9 (11.8) High (1,001-2,499 µg/l) 26 (34	None	9 (11.1)
> 5 5 (6.2) Siblings with thalassemia No No 59 (72.8) Yes 22 (27.2) Academic performance 9 (56.5) Good 19 (27.5) Average 39 (56.5) Low 11 (16.0) Age of diagnosis 0 0-12 month 51 (75.0) 1-2 years 12 (17.6) > 2 years 5 (7.4) Chelation None None 6 (8.7) Oral 21 (30.4) Injectable 16 (23.1) Both 26 (37.7) Blood transfusion 0 Once a week 12 (15.2) Once every 2 weeks 44 (55.7) Once every 4 weeks 2 (2.5) Hemoglobin level (gm%) 6-7 6-7 13 (16.0) 8-9 60 (74.1) > 9 8 (9.9) Ferritin level Normal (≤ 1,000 µg/l) 9 (11.8) High (1,001-2,499 µg/l) 26 (34.2) Very high (≥ 2,500 µg/l) Very high (≥ 2,500 µg/l) 41 (53.9) Bon	1-2	44 (54.3)
Siblings with thalassemia No 59 (72.8) Yes 22 (27.2) Academic performance Good 19 (27.5) Average 39 (56.5) Low 11 (16.0) Age of diagnosis 0-12 month 51 (75.0) 1-2 years 12 (17.6) > 2 years 12 (17.6) > 12 (10.4) Injectable 16 (23.1) Both 26 (37.7) Blood transfusion Once a week 12 (15.2) Once every 2 weeks 44 (55.7) Once every 4 weeks 21 (26.6) Once in > 4 weeks 22 (2.5) Hemoglobin level (gm%) 6-7 13 (16.0) 8-9 60 (74.1) > 9 8 (9.9) Ferritin level Normal (≤ 1,000 µg/l) 9 (11.8) High (1,001-2,499 µg/l) 26 (34.2) Very high (≥ 2,500 µg/l) 41 (53.9) Bone marrow transplant No 75 (92.6)	3-5	23 (28.4)
No59 (72.8)Yes22 (27.2)Academic performance90 (56.5)Good19 (27.5)Average39 (56.5)Low11 (16.0)Age of diagnosis12 (17.6)0-12 month51 (75.0)1-2 years12 (17.6)> 2 years57.4)Chelation12 (30.4)None6 (8.7)Oral21 (30.4)Injectable16 (23.1)Both26 (37.7)Blood transfusion12 (15.2)Once a week12 (15.2)Once every 2 weeks44 (55.7)Once every 4 weeks2 (2.5)Hemoglobin level (gm%)6-76-713 (16.0)8-960 (74.1)> 98 (9.9)Ferritin level9 (11.8)High (1,001-2,499 µg/l)26 (34.2)Very high (≥ 2,500 µg/l)41 (53.9)Bone marrow transplantNoNo75 (92.6)	> 5	5 (6.2)
Yes 22 (27.2) Academic performance 9 Good 19 (27.5) Average 39 (56.5) Low 11 (16.0) Age of diagnosis 9 0-12 month 51 (75.0) 1-2 years 12 (17.6) > 2 years 5 (7.4) Chelation 8 None 6 (8.7) Oral 21 (30.4) Injectable 16 (23.1) Both 26 (37.7) Blood transfusion 2 Once a week 12 (15.2) Once every 2 weeks 44 (55.7) Once every 4 weeks 2 (2.5) Hemoglobin level (gm%) 6-7 6-7 13 (16.0) 8-9 60 (74.1) > 9 8 (9.9) Ferritin level 9 Normal ($\leq 1,000 \mu g/l$) 9 (11.8) High (1,001-2,499 µg/l) 26 (34.2) Very high ($\geq 2,500 \mu g/l$) 41 (53.9) Bone marrow transplant 75 (92.6)	Siblings with thalassemia	
Academic performance I9 (27.5) Average 39 (56.5) Low 11 (16.0) Age of diagnosis $11 (16.0)$ Age of diagnosis $12 (17.6)$ $0-12 month$ $51 (75.0)$ $1-2 years$ $5 (7.4)$ Chelation $12 (17.6)$ None $6 (8.7)$ Oral $21 (30.4)$ Injectable $16 (23.1)$ Both $26 (37.7)$ Blood transfusion 0 Once a week $12 (15.2)$ Once every 2 weeks $44 (55.7)$ Once every 4 weeks $2 (2.5)$ Hemoglobin level (gm%) $6-7$ $6-7$ $13 (16.0)$ $8-9$ $8 (9.9)$ Ferritin level 9 Normal ($\leq 1,000 \mu g/l$) $9 (11.8)$ High (1,001-2,499 \mu g/l) $26 (34.2)$ Very high ($\geq 2,500 \mu g/l$) $41 (53.9)$ Bone marrow transplant N_0 No $75 (92.6)$	No	59 (72.8)
Good19 (27.5)Average39 (56.5)Low11 (16.0)Age of diagnosis $-12 \mod h$ 0-12 $\mod h$ 51 (75.0)1-2 years12 (17.6)> 2 years5 (7.4)Chelation $-12 \mod h$ None6 (8.7)Oral21 (30.4)Injectable16 (23.1)Both26 (37.7)Blood transfusion $-12 (15.2)$ Once a week12 (15.2)Once every 2 weeks44 (55.7)Once every 4 weeks2 (2.5)Hemoglobin level (gm%) -7 $6-7$ 13 (16.0) $8-9$ $60 (74.1)$ > 9 $8 (9.9)$ Ferritin level -9 Normal ($\leq 1,000 \ \mu g/l$) $9 (11.8)$ High (1,001-2,499 \ \mu g/l) $26 (34.2)$ Very high ($\geq 2,500 \ \mu g/l$) $41 (53.9)$ Bone marrow transplant $-75 (92.6)$	Yes	22 (27.2)
Average 39 (56.5) Low 11 (16.0) Age of diagnosis 51 (75.0) 0-12 month 51 (75.0) 1-2 years 12 (17.6) > 2 years 5 (7.4) Chelation 6 (8.7) None 6 (8.7) Oral 21 (30.4) Injectable 16 (23.1) Both 26 (37.7) Blood transfusion 0nce a week Once a week 12 (15.2) Once every 2 weeks 44 (55.7) Once every 4 weeks 2 (2.5) Hemoglobin level (gm%) 6-7 6-7 13 (16.0) 8-9 60 (74.1) > 9 8 (9.9) Ferritin level 9 Normal (≤ 1,000 µg/l) 9 (11.8) High (1,001-2,499 µg/l) 26 (34.2) Very high (≥ 2,500 µg/l) 41 (53.9) Bone marrow transplant No No 75 (92.6)	Academic performance	
Low 11 (16.0) Age of diagnosis 0-12 month 51 (75.0) 1-2 years 12 (17.6) > 2 years 5 (7.4) Chelation None 6 (8.7) Oral 21 (30.4) Injectable 16 (23.1) Both 26 (37.7) Blood transfusion Once a week 12 (15.2) Once every 2 weeks 44 (55.7) Once every 4 weeks 21 (26.6) Once in > 4 weeks 22 (2.5) Hemoglobin level (gm%) 6-7 13 (16.0) 8-9 60 (74.1) > 9 8 (9.9) Ferritin level Normal (≤ 1,000 µg/l) 9 (11.8) High (1,001-2,499 µg/l) 26 (34.2) Very high (≥ 2,500 µg/l) 41 (53.9) Bone marrow transplant No 75 (92.6)	Good	19 (27.5)
Age of diagnosis 51 (75.0) 1-2 years 12 (17.6) > 2 years 5 (7.4) Chelation None 6 (8.7) Oral 21 (30.4) Injectable 16 (23.1) Both 26 (37.7) Blood transfusion Once a week 12 (15.2) Once every 2 weeks 44 (55.7) Once every 4 weeks 21 (26.6) Once in > 4 weeks 2 (2.5) Hemoglobin level (gm%) 6.7 6-7 13 (16.0) 8-9 60 (74.1) > 9 8 (9.9) Ferritin level 9 (11.8) High (1,001-2,499 µg/l) 26 (34.2) Very high (≥ 2,500 µg/l) 41 (53.9) Bone marrow transplant No No 75 (92.6)	Average	39 (56.5)
0-12 month 51 (75.0) 1-2 years 12 (17.6) > 2 years 5 (7.4) Chelation None 6 (8.7) Oral 21 (30.4) Injectable 16 (23.1) Both 26 (37.7) Blood transfusion Once a week 12 (15.2) Once every 2 weeks 44 (55.7) Once every 4 weeks 21 (26.6) Once in > 4 weeks 2 (2.5) Hemoglobin level (gm%) 6-7 13 (16.0) 8-9 60 (74.1) > 9 8 (9.9) Ferritin level Normal (≤ 1,000 µg/l) 9 (11.8) High (1,001-2,499 µg/l) 26 (34.2) Very high (≥ 2,500 µg/l) 41 (53.9) Bone marrow transplant No 75 (92.6)	Low	11 (16.0)
1-2 years 12 (17.6) > 2 years 5 (7.4) Chelation None 6 (8.7) Oral 21 (30.4) Injectable 16 (23.1) Both 26 (37.7) Blood transfusion Once a week 12 (15.2) Once every 2 weeks 44 (55.7) Once every 4 weeks 21 (26.6) Once in > 4 weeks 2 (2.5) Hemoglobin level (gm%) 6-7 6-7 13 (16.0) 8-9 60 (74.1) > 9 8 (9.9) Ferritin level 9 (11.8) High (1,001-2,499 µg/l) 26 (34.2) Very high (≥ 2,500 µg/l) 41 (53.9) Bone marrow transplant No No 75 (92.6)	Age of diagnosis	
> 2 years5 (7.4)Chelation6 (8.7)None6 (8.7)Oral21 (30.4)Injectable16 (23.1)Both26 (37.7)Blood transfusion0nce a weekOnce a week12 (15.2)Once every 2 weeks44 (55.7)Once every 4 weeks21 (26.6)Once in > 4 weeks2 (2.5)Hemoglobin level (gm%)6-76-713 (16.0)8-960 (74.1)> 98 (9.9)Ferritin level9Normal (≤ 1,000 µg/l)9 (11.8)High (1,001-2,499 µg/l)26 (34.2)Very high (≥ 2,500 µg/l)41 (53.9)Bone marrow transplantNoNo75 (92.6)	0-12 month	51 (75.0)
Chelation 6 (8.7) None 6 (8.7) Oral 21 (30.4) Injectable 16 (23.1) Both 26 (37.7) Blood transfusion 0nce a week Once a week 12 (15.2) Once every 2 weeks 44 (55.7) Once every 4 weeks 21 (26.6) Once in > 4 weeks 2 (2.5) Hemoglobin level (gm%) 6-7 6-7 13 (16.0) 8-9 60 (74.1) > 9 8 (9.9) Ferritin level 9 (11.8) High (1,001-2,499 µg/l) 26 (34.2) Very high (≥ 2,500 µg/l) 41 (53.9) Bone marrow transplant No No 75 (92.6)	1-2 years	12 (17.6)
None6 (8.7)Oral21 (30.4)Injectable16 (23.1)Both26 (37.7)Blood transfusion26 (37.7)Once a week12 (15.2)Once every 2 weeks44 (55.7)Once every 4 weeks21 (26.6)Once in > 4 weeks2 (2.5)Hemoglobin level (gm%)6-76-713 (16.0)8-960 (74.1)> 98 (9.9)Ferritin level9Normal (≤ 1,000 µg/l)9 (11.8)High (1,001-2,499 µg/l)26 (34.2)Very high (≥ 2,500 µg/l)41 (53.9)Bone marrow transplantNoNo75 (92.6)	> 2 years	5 (7.4)
Oral21 (30.4)Injectable16 (23.1)Both26 (37.7)Blood transfusion26 (37.7)Once a week12 (15.2)Once every 2 weeks44 (55.7)Once every 4 weeks21 (26.6)Once in > 4 weeks2 (2.5)Hemoglobin level (gm%)6-76-713 (16.0)8-960 (74.1)> 98 (9.9)Ferritin level9Normal ($\leq 1,000 \mu g/l$)9 (11.8)High (1,001-2,499 $\mu g/l$)26 (34.2)Very high ($\geq 2,500 \mu g/l$)41 (53.9)Bone marrow transplant75 (92.6)	Chelation	
Injectable 16 (23.1) Both 26 (37.7) Blood transfusion 26 (37.7) Once a week 12 (15.2) Once every 2 weeks 44 (55.7) Once every 4 weeks 21 (26.6) Once in > 4 weeks 2 (2.5) Hemoglobin level (gm%) 6-7 6-7 13 (16.0) 8-9 60 (74.1) > 9 8 (9.9) Ferritin level 9 (11.8) High (1,001-2,499 µg/l) 26 (34.2) Very high (≥ 2,500 µg/l) 41 (53.9) Bone marrow transplant No No 75 (92.6)	None	6 (8.7)
Both 26 (37.7) Blood transfusion 12 (15.2) Once a week 12 (15.2) Once every 2 weeks 44 (55.7) Once every 4 weeks 21 (26.6) Once in > 4 weeks 2 (2.5) Hemoglobin level (gm%) 6-7 6-7 13 (16.0) 8-9 60 (74.1) > 9 8 (9.9) Ferritin level 9 Normal ($\leq 1,000 \mu g/l$) 9 (11.8) High (1,001-2,499 $ \mu g/l$) 26 (34.2) Very high ($\geq 2,500 \mu g/l$) 41 (53.9) Bone marrow transplant No No 75 (92.6)	Oral	21 (30.4)
Blood transfusion 12 (15.2) Once a week 12 (15.2) Once every 2 weeks 44 (55.7) Once every 4 weeks 21 (26.6) Once in > 4 weeks 2 (2.5) Hemoglobin level (gm%) 6-7 6-7 13 (16.0) 8-9 60 (74.1) > 9 8 (9.9) Ferritin level 9 Normal (≤ 1,000 µg/l) 9 (11.8) High (1,001-2,499 µg/l) 26 (34.2) Very high (≥ 2,500 µg/l) 41 (53.9) Bone marrow transplant No No 75 (92.6)	Injectable	16 (23.1)
$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	Both	26 (37.7)
Once every 2 weeks44 (55.7)Once every 4 weeks21 (26.6)Once in > 4 weeks2 (2.5)Hemoglobin level (gm%) $(6-7)$ $6-7$ 13 (16.0) $8-9$ 60 (74.1)> 98 (9.9)Ferritin level (1.8) Normal ($\leq 1,000 \ \mu g/l$)9 (11.8)High (1,001-2,499 \ \mu g/l)26 (34.2)Very high ($\geq 2,500 \ \mu g/l$)41 (53.9)Bone marrow transplant No No75 (92.6)	Blood transfusion	
Once every 4 weeks $21 (26.6)$ Once in > 4 weeks $2 (2.5)$ Hemoglobin level (gm%) $2 (2.5)$ $6-7$ $13 (16.0)$ $8-9$ $60 (74.1)$ > 9 $8 (9.9)$ Ferritin level $8 (9.9)$ Normal ($\leq 1,000 \mu g/l$) $9 (11.8)$ High (1,001-2,499 $\mu g/l$) $26 (34.2)$ Very high ($\geq 2,500 \mu g/l$) $41 (53.9)$ Bone marrow transplant $75 (92.6)$	Once a week	12 (15.2)
Once in > 4 weeks2 (2.5)Hemoglobin level (gm%) $(6-7)$ 13 (16.0) $6-7$ 13 (16.0) $8-9$ 60 (74.1)> 98 (9.9)Ferritin level $(5 - 1000 \mu g/l)$ Normal ($\leq 1,000 \mu g/l$)9 (11.8)High (1,001-2,499 \mu g/l)26 (34.2)Very high ($\geq 2,500 \mu g/l$)41 (53.9)Bone marrow transplant $75 (92.6)$	Once every 2 weeks	44 (55.7)
Hemoglobin level (gm%)13 (16.0) $6-7$ 13 (16.0) $8-9$ 60 (74.1)> 98 (9.9)Ferritin level 8 Normal ($\leq 1,000 \ \mu g/l$)9 (11.8)High (1,001-2,499 \ \mu g/l)26 (34.2)Very high ($\geq 2,500 \ \mu g/l$)41 (53.9)Bone marrow transplant $75 (92.6)$	Once every 4 weeks	21 (26.6)
6-713 (16.0)8-960 (74.1)> 98 (9.9)Ferritin level9Normal (≤ 1,000 µg/l)9 (11.8)High (1,001-2,499 µg/l)26 (34.2)Very high (≥ 2,500 µg/l)41 (53.9)Bone marrow transplant75 (92.6)	Once in > 4 weeks	2 (2.5)
8-9 60 (74.1) > 9 8 (9.9) Ferritin level 9 Normal (≤ 1,000 µg/l) 9 (11.8) High (1,001-2,499 µg/l) 26 (34.2) Very high (≥ 2,500 µg/l) 41 (53.9) Bone marrow transplant 75 (92.6)	Hemoglobin level (gm%)	
> 9 8 (9.9) Ferritin level Normal (≤ 1,000 µg/l) 9 (11.8) High (1,001-2,499 µg/l) 26 (34.2) Very high (≥ 2,500 µg/l) 41 (53.9) Bone marrow transplant No 75 (92.6)	6-7	13 (16.0)
Ferritin level 9 (11.8) Normal ($\leq 1,000 \ \mu g/l$) 9 (11.8) High (1,001-2,499 \ \mu g/l) 26 (34.2) Very high ($\geq 2,500 \ \mu g/l$) 41 (53.9) Bone marrow transplant 75 (92.6)	8-9	60 (74.1)
Normal (≤ 1,000 μg/l) 9 (11.8) High (1,001-2,499 μg/l) 26 (34.2) Very high (≥ 2,500 μg/l) 41 (53.9) Bone marrow transplant 75 (92.6)	> 9	8 (9.9)
High (1,001-2,499 μg/l) 26 (34.2) Very high (≥ 2,500 μg/l) 41 (53.9) Bone marrow transplant 75 (92.6)	Ferritin level	
High (1,001-2,499 μg/l) 26 (34.2) Very high (≥ 2,500 μg/l) 41 (53.9) Bone marrow transplant 75 (92.6)	Normal ($\leq 1,000 \ \mu g/l$)	9 (11.8)
Bone marrow transplant No 75 (92.6)		26 (34.2)
No 75 (92.6)	Very high ($\geq 2,500 \ \mu g/l$)	41 (53.9)
	Bone marrow transplant	
Yes 6 (7.4)	No	75 (92.6)
	Yes	6 (7.4)

cal management of thalassemia. However the psychosocial aspects of the condition are not given much weightage. No similar study has been conducted in the country, and hence this study is hoped to provide a framework for further research, as well as push towards integration of psychological support into the program. With this study the authors hope to make a difference towards improving these children's lives, by submitting a recommendation based on the findings of the study to the local authorities. The study was done with the, intention of stressing the importance of the integration of psychosocial support into the current treatment program.

Table 2. Quality of life of in 81 adolescents (age 10-19) with beta-thalassemia major in the Maldives

	Mean (95% CI)
Physical functioning	80.50 (76.42, 84.57)
Emotional functioning	72.30 (67.23, 77.32)
Social functioning	88.18 (84.23,92.14)
School functioning	76.44 (71.66, 81.21)
Psychosocial functioning	78.96 (75.04, 82.88)
Total functioning	79.50 (75.84, 83.15)

METHODS

The research was approved by Human Research Ethic Committee, USM and Research Committee, Ministry of Health Maldives. This cross-sectional study was conducted from March to May 2013 at the National Thalassemia and Other Haemoglobinopathies Center (NTC), Maldives Blood Services, Maldives. This centre functions as the national referral centre for those suspected or diagnosed with thalassemia, and all thalassemia patients need to be registered here. As of August 2014, a cumulative total of 803 thalassemia patients were registered and a total of 563 were living¹⁾.

The inclusion criteria were; 1) subjects who had been diagnosed with beta-thalassemia major, and was on regular follow-up under NTC, 2) undergoing regular blood transfusion at NTC, 3) adolescents age 10 to 19 years, and 4) able to comprehend English. The exclusion criteria were; 1) had been diagnosed with a psychiatric disorder, 2) family history of mental illness, as this could contribute to emotional distress due to genetic loading and stressful surrounding, 3) patients positive for human immune-deficiency virus.

All patients who fulfilled the criteria during the study period were included after obtaining an informed consent which was available in both English and Dhivehi (national Maldivian language). The questionnaires were given in an envelope, which they were required to fill up and put back in the envelope and seal. The questionnaires were filled up while they were getting their blood transfusion in a cubical with adequate privacy. For those who just came for consultation, they were given a private room to sit and fill in the questionnaires. Medical records were referred to gather clinical information such as hemoglobin and ferritin level.

The Pediatric Quality of Life Inventory (PedsQL) is 23-item questionnaire to measure health-related quality of life (HRQOL) in healthy children, adolescents and those with acute and chronic health conditions. It comprises 4 multidimensional scales; physical (8 items), emotional (5 items), social (5 items), and school functioning (5 items). Scores comprise of total (23 items), physical Health Summary Score (HSS) (8 items) and psychosocial HSS (15 items). Higher PedsQL scores reflect higher HRQOL. The scale is valid and reliable with an internal consistency 0.88 in child self-report and 0.90 for the parent proxy-report¹⁸.

Descriptive statistical analyses were performed for socio-demographic and clinical characteristic using Statistical Packages for Social Sciences (SPSS) version 19 software.

RESULTS

Ninety patients were approached during the study period. A total of 81 subjects were analyzed after exclusion of 9 patients due to reasons such as refusal, inability to understand English, and not returning or completing the questionnaires.

The sample consists of 56.8% female, mean age 15.7 years with majority in older age group. Majority of the subjects were schooling (73.4%). Only a few subjects pursued their studies beyond 10th standard, or their London Ordinary levels. In term of academic performance, majority of them (56.5%) obtained an average result, which was classified either a B or C grades, while 27.5% obtained an A grade or good result and 15.9% obtained a poor result which was categorized as D and below. Twelve subjects did not indicate the last result they obtained.

The parental characteristics showed that the majority of parents were married (75.3%). The rest of the subjects had a single parent of

which 16% divorced, 6.2% separated and 2.5% widowed. This is different from the national data, as the Maldives has one of the highest rates of divorce at $49\%^{(9)}$.

The education level of mothers was mostly at secondary level (53.1%), followed by 39.5% primary and 7.4% tertiary level. In contrast, most fathers had an educational level of primary or below (46.8%) and held non-professional jobs (84.9%). The remaining 41.8% and 11.4% had secondary or tertiary level of education, respectively. National statistics show a male to female ratio of 0.9 in primary education in 1999-2011, a 1.2 ratio in secondary education from 1999-2000 and a ratio of 1.9 in 2003 which had fallen to 0.8 in tertiary education¹⁹.

Almost two thirds (65.4%) of the mothers were housewives and among those who held jobs, 27.2% had non-professional jobs and only 7.4% had professional jobs. Amongst the fathers, 11% had a professional jobs, while 4,1% were unemployed. The Maldives has an unemployment rate of more than one in four economically active young being unemployed in general. Unemployment rates among female is 3 times higher than male.

About three quarters (75.6%) of them were diagnosed before 1 year of age, and only 7.4% being diagnosed after 2 years of age. Most of the subjects received blood transfusion once in every 2 weeks (55.7%), followed by 26.6% in every 4 weeks, 15.2% every week, and 2.6% once a month.

More than a third (37.7%) of subjects was on both oral and injectable chelator, whereas 30.4% and 23.2% were on oral or subcutaneous deferoxamine alone, respectively. It should be noted 7.4% were not on any chelator and this might be the 6 patients who had undergone bone marrow transplant.

The mean hemoglobin (Hb) level was 8.35 (SD 0.95). 42% of subjects had a hemoglobin level of 9 gm%, with another 32.1% having an Hb of 8 gm%. Only 1 participant had an Hb of 11, and another 2 had an Hb of 6 gm%.

The mean ferritin level was 3,339.6 µg/l ranging from 400 to 13,000 µg/l. Due to the vast difference in the range, the ferritin levels were categorized into normal (\leq 1,000 µg/l), high (1,001-2499 µg/l), and very high (\geq 2,500 µg/l) level. Majority of patients had a ferritin levels in the high category (53.9%), and only 11.8% patient was in the normal category.

Almost two thirds (63%) of patients claimed they did not have any medical complications. Amongst the one third (37%) with complications, 81.5% and 17.3% had liver-related or hormone-related complications. The less common complications were related to infection (7.4%) and spleen (6.2%).

Subjects had a mean number of 1.2 admissions to hospital for reasons other than blood transfusion since their diagnosis. 35.8% had no admission while 23.5% had 2 admissions. The highest number of admission was 10 in one (1.2%) patient.

Most patients (55.7%) claimed they were always compliant, while the rest claimed to be compliant sometimes, rarely or not at all at 29.1%, 7.6% and 7.6%, respectively.

The mean level of physical, emotional, social and school functioning was 80.50, 72.30, 88.18 and 76.44, respectively. The mean level for subtotal psychosocial HSS and total functioning was 78.96 and 79.50, respectively. The emotional functioning was lowest, while the social functioning was highest in this study sample.

DISCUSSION

The World Health Organization Quality of Life Assessment (WHOQOL) group defines Quality of Life (QOL) as an individual's perception of their position in life, in the context of culture and value systems in which they live and in relation to their goals, expectations, standards and concerns²⁰. This definition by the work group shows that quality of life is deeply intertwined with culture and religion, as well as variety of other factors, which can contribute to psychological distress in patients living with beta-thalassemia major.

The HRQOL in this study was comparable to a similar study conducted in Thailand using the same scale, with 2-8 points difference in most domains²¹). Like the current study, the domain with the highest score was social functioning and lowest was that of emotional functioning. Similar impairment in emotional functioning has also been reported in a study conducted in the United States²²).

The current study showed that the HRQOL of this group was comparable to the levels present in healthy controls in Malaysia²³. However, the findings were consistent with the Thai study²¹. Similar results could possibly mean that the Thai population was more similar to that of the current population in term of the care they receive and the life experiences. Like the Maldives, Thailand also considers thalassemia a public health problem and has been running several preventive programs since the early 1990s.

A possible explanation for the discordance between the Maldivian and Malaysian thalassemia group could be that the study was conducted one centre in the capital. The control population came from an urban area with hectic lifestyle, which involved travelling and long hours at school and tuitions. Life in the Maldives is different in this sense, especially as Malé, which is the capital is only 3 square km. This removes a lot of hassle involved in logistics and allows children to spend more time at home. In a study,²⁴ longer clinic admission was a significant determinant of reduced physical health quality of life. Another possible explanation for this could be the national thalassemia program which had been in place since 1994, which has increased the awareness among the thalassemia population and their family as well as the general public.

The mean total functioning scores were different between males (83.29) and females (75.29), by nearly 8 points. On further analysis, a difference of 10 points was found in the level of physical and psychosocial functioning between the genders as well. This difference was further analyzed using the t-test, which showed that a significant mean difference existed between males and females in both total and psychosocial functioning.

Previous studies have also consistently shown that there are lower levels of HRQOL amongst girls when compared to boys²⁵⁾. The possible explanation for this gender difference might be the presence of emotional distress in more number of female patients, which translate to poorer HRQOL when compared to males. Apart from that, restricted social roles, culture, low self-esteem, failure in heterosexual relationships, could play a major role in how girls perceived their HRQOL²⁶⁾.

Academic performance was obtained in an attempt to understand how much living with thalassemia affected them. The study showed that 56.5% and 27.5% obtained an average (B or C report) or a good (A report) result, respectively. This achievement was comparable to that of average adolescents in the United States, as shown in a study where 59% obtained an average and 31% received mostly A's. In contrast, several studies have demonstrated that academic performance of thalassemia children was lower than in the normal population²³).

In the Maldives, 70% of the thalassemia children and adolescents were attending school, whereas in an Indian study more than half were not attending school²⁷). Other reasons given for poor academic performances in previous studies were being away from school for various thalassemia-related issues^{10,28}. The NTC stays open till 9 pm and Saturdays as well, which makes it flexible and missing school can be avoided. In addition, various awareness campaigns have been run in the Maldives, stressing on the fact that thalassemia children are no different from any other child. Great emphasis has been placed on "normalizing" the lives of these children by organization such as Society for Health Education (SHE).

While conducting the study, the first author also noticed that most children and adolescents came with their books to the daycare centre and would complete their homework while getting transfused. On conversing with the participants, most of them had ambitions and wanted to pursue their studies further, showing that they did not view themselves as being any different academically.

Nearly one fourth of the patients were taken care of by a single parent. Parents of thalassemia children experience high psychosocial burden, in term of disease chronicity, treatment modalities, morbidities and mortality due to complications^{10,29)}. A study in India, similarly reported greater psychosocial burden as well as poor overall QOL and perception of health in parents of thalassemia children¹⁴⁾.

Most of the participants (55.7%), received a transfusion every two weeks and half (53.5%) were on injectable chelators. The analysis showed that the mean level of ferritin for the study group was 3,339 µg/l. A ferritin level of < 1,000 µg/l is recommended by the Iron Health Alliance, US for those children receiving regular blood transfusion. A level above 2,500 µg/l puts the child at risk of cardiac complications. Further analysis of the data showed that only 11.8% had ferritin levels below the recommended level, whereas 53.9% had levels above 2,500 µg/l, putting them at high risk for further complications. Low HRQOL is associated with high ferritin level³⁰, use of injectable chelator³¹, and complications like cardiac condition, short stature and other metabolic conditions^{32,33}.

The first author worked in NTC for a short duration of time, and on interviewing the children, some of them justified their reason for non-compliance by stating "there was no point', as they were going to die anyway. Non-compliance is associated with the use of injectable chelators³⁴, psychosocial issues³⁵, and older age¹¹. In this study, half of the subjects used intravenous deferoxamine and age above 15, which may account for high level of non-compliance. Older patients had poorer social functioning probably because of increased awareness about the impact of the disease on finding gainful employment, marriage, and parenthood³⁶.

CONCLUSIONS

Adolescents with beta-thalassemia major in the Maldives have reduced HRQOL. The high ferritin level could be associated with lower HRQOL and hence an attempt should be made towards lowering ferritin and improving compliance to chelation treatments. The gender difference in HRQOL signifies the need for more attention to the female patients and for areas of improvement to be explored.

REFERENCES

- 1) Angastiniotis M. The Maldives: WHO Mission August 2014. Thalassaemia International Federation, Nicosia. 2014
- Firdous N, Gibbons S, Modell B. Falling prevalence of beta-thalassaemia and eradication of malaria in the Maldives. J Community Genet 2011; 2(3): 173-89.
- Mustafa I. The crisis of iron in transfusion medicine: improved iron chelation therapy and its implications for clinical practice in the Maldives (Doctoral dissertation, University of British Columbia).
- 4) Waheed F, Fisher C, Awofeso A, et al. Carrier screening for beta-thalassemia in the Maldives: perceptions of parents of affected children who did not take part in screening and its consequences. J Community Genet 2016; 7(3): 243-253.
- 5) De Sanctis V, Soliman AT, Elsedfy H, et al. Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia (I-CET) position statement and guidelines. Indian J Endocrinol Metab 2013; 17(1): 8-18.
- Belhoul KM, Bakir ML, Saned MS, et al. Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major. Ann Hematol 2012; 91(7): 1107-14.
- 7) Azami M, Sharifi A, Norozi S, *et al.* Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in patients with thalassemia major in Iran: A meta-analysis study. Caspian J Intern Med 2017; 8(1): 1-15.
- Bazi A, Sharifi-Rad J, Rostami D, *et al.* Diabetes Mellitus in Thalassaemia Major Patients: A Report from the Southeast of Iran. J Clin Diagn Res 2017; 11(5): BC01-BC04.
- 9) Sharma S, Dutt N, Sidhu M, et al. Prevalence of hypothyroidism, diabetes mellitus and delayed puberty in patients of thalassemia major in a tertiary care center of Jammu province, Jammu Kashmir, India. Int J Adv Med 2017; 4(3): 673-7.
- Wahab IA, Naznin M, Nora MZ, et al. Thalassemia: a study on the perception of patients and family members. Med J Malays 2011; 66(4): 326-34.
- Evangeli M, Mughal K, Porter JB. Which psychosocial factors are related to chelation adherence in thalassemia? A systematic review. Hemoglobin 2010; 34(3): 305-21.
- 12) Ahmad N, Ismail A, Sulong S, *et al.* Determinant for Quality of Life among Childhood Asthma in Malaysia: A Cross Sectional Study. Int Med J 2017; 24(2): 195-199.
- 13) Abdul-Zahra HA, Hassan MK, Ahmed BA. Health-related Quality of Life in Children

and Adolescents With β-Thalassemia Major on Different Iron Chelators in Basra, Iraq. J Pediatr Hematol Oncol. 2016; 38(7): 503-11.

- 14) Sharma S, Seth B, Jawade P, et al. Quality of Life in Children with Thalassemia and their Caregivers in India. Indian J Pediatr 2017; 84(3): 188-194.
- 15) Grewal NK, Sodhi C, Sobti P. To study the quality of life and its relation with socioeconomic status in thalassemic adolescents in a tertiary care center. CHRISMED J Health Res 2017; 4(1): 33.
- 16) Sultana R, Humayun S, Noor T, et al. Impact of Thalassaemia on Quality of Life. J Soc Obs Gyn Pakistan 2017; 6(4): 156-60.
- 17) Adam S, Afifi H, Thomas M, et al. Quality of Life Outcomes in a Pediatric Thalassemia Population in Egypt. Hemoglobin 2017; 41(1): 16-20.
- 18) Varni JW, Seid M, Kurtin PS. PedsQL 4.0: Reliability and validity of the Pediatric Quality of Life Inventory[™] Version 4.0 Generic Core Scales in healthy and patient populations. Med Care 2001; 39(8): 800-12.
- National Bureau of Statistics Maldives: population and housing Cencus 2014. Ministry of Finance & Treasury, Maldives.
- Skevington SM. Advancing cross-cultural research on quality of life: observations drawn from the WHOQOL development. Qual Life Res 2002; 11(2): 135-44.
- 21) Thavorncharoensap M, Torcharus K, Nuchprayoon I, et al. Factors affecting health-related quality of life in Thai children with thalassemia. BMC Hematology 2010; 10(1): 1.
- 22) Pakbaz Z, Treadwell M, Yamashita R, et al. Quality of life in patients with thalassemia intermedia compared to thalassemia major. Ann N Y Acad Sci 2005; 1054(1): 457-61.
- 23) Ismail A, Campbell MJ, Ibrahim HM, et al. Health related quality of life in Malaysian children with thalassaemia. Health Qual Life Outcomes 2006; 4(1): 39.
- 24) Beamish P, Patel P, da Silva T, et al. Examining depression and quality of life in patients with Thalassemia in Sri Lanka. Ann Glob Health 2016; 82(3): 551-2.
- 25) Shaligram D, Girimaji SC, Chaturvedi SK. Psychological problems and quality of life in children with thalassemia. Indian J Pediatr 2007; 74(8): 727-30.
- 26) Koutelekos J, Haliasos N. Depression and Thalassemia in children, adolescents and adults. Health Sci J 2013; 7(3): 239-246
- 27) Guha P, Talukdar A, De A, *et al.* Behavioral profile and school performance of thalassemia children in Eastern India. Asian J Pharm Clin Res 2013; 6(2): 49-52.
- 28) Gharaibeh H, Amarneh BH, Zamzam SZ. The psychological burden of patients with beta thalassemia major in Svria. Pediatr Int 2009; 51(5): 630-6.
- Aydinok Y, Erermis S, Bukusoglu N, et al Psychosocial implications of thalassemia major. Pediatr Int 2005; 47(1): 84-9.
- Tuysuz G, Tayfun F. Health-related Quality of Life and its Predictors Among Transfusion-dependent Thalassemia Patients. J Pediatr Hematol Oncol 2017; 39(5): 332-336.
- 31) Seyedifar M, Dorkoosh FA, Hamidieh AA, et al. Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran. Int J Hematol Oncol Stem Cell Res 2016; 10(4): 224-231.
- 32) Shamshirsaz AA, Bekheirnia MR, Kamgar M, et al. Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran. BMC Endocr Disord 2003; 3(1): 4.
- 33) Boonchooduang N, Louthrenoo O, Choeyprasert W, et al. Health-Related Quality of Life in Adolescents with Thalassemia. Pediatr Hematol Oncol 2015; 32(5): 341-8.
- 34) Yahia M. Increasing compliance in thalassemia treatment. Nature Middle East. 2009.
- 35) Musallam K, Cappellini MD, Taher A. Challenges associated with prolonged survival of patients with thalassemia: transitioning from childhood to adulthood. Pediatrics 2008; 121(5): e1426-9.
- 36) Soni S, Thawani R, Idhate T, et al. Health Related Quality of Life in Patients with Transfusion-dependent Thalassemia. Indian Pediatr 2016; 53(8): 741-2.